Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting

By Keetch D.W.   Andriole G.L.   Ratliff T.L.   Catalona W.J.  

Urology, Vol. 50, Iss. 6, 1997-12 ,pp. : 901-905

Elsevier

Access to resources Recommend Favorite

Can finasteride reverse the progress of benign prostatic hyperplasia? a two-year placebo-controlled study

By Andersen J.T.   Ekman P.   Wolf H.   Beisland H.O.   Johansson J.E.   Kontturi M.   Lehtonen T.   Tveter K.  

Urology, Vol. 46, Iss. 5, 1995-11 ,pp. : 631-637

Elsevier

Access to resources Recommend Favorite

Effect of finasteride on serum testosterone in men with benign prostatic hyperplasia and low testosterone levels

By Roehrborn C.   PLESS Study Group  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 160-160

Elsevier

Access to resources Recommend Favorite

Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up

By Lam J.S.   Romas N.A.   Lowe F.C.  

Urology, Vol. 61, Iss. 2, 2003-02 ,pp. : 354-358

Elsevier

Access to resources Recommend Favorite

Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia

By Vaughan D.   Imperato-McGinley J.   McConnell J.   Matsumoto A.M.   Bracken B.   Roy J.   Sullivan M.   Pappas F.   Cook T.   Daurio C.   Meehan A.   Stoner E.   Waldstreicher J.  

Urology, Vol. 60, Iss. 6, 2002-12 ,pp. : 1040-1044

Elsevier

Access to resources Recommend Favorite